Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$7.94
-0.07-0.87%
At close: May 14, 5:00 PM EST
$8.17
0.232.90%
After Hours: 7:19 PM EST
ARS Pharmaceuticals Inc Analyst Ratings
SPRYNASDAQ
Earnings: Q1 2026 earnings announcement before the market open today
ARS Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:SPRY | Benzinga
ARS Pharmaceuticals Inc has a consensus price target of $29 based on the ratings of 7 analysts. The high is $40 issued by Roth Capital on September 4, 2025. The low is $19 issued by Wedbush on March 11, 2024. The 3 most-recent analyst ratings were released by Roth Capital, Scotiabank, and Raymond James on September 4, 2025, March 7, 2025, and January 14, 2025, respectively. With an average price target of $32.67 between Roth Capital, Scotiabank, and Raymond James, there's an implied 299.84% upside for ARS Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Roth Capital
Scotiabank
Raymond James
Leerink Partners
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for ARS Pharmaceuticals
Loading calendar...
FAQ
What is the target price for ARS Pharmaceuticals (SPRY) stock?
The latest price target for ARS Pharmaceuticals (NASDAQ:SPRY) was reported by Roth Capital on September 4, 2025. The analyst firm set a price target for $40.00 expecting SPRY to rise to within 12 months (a possible 389.60% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ARS Pharmaceuticals (SPRY)?
The latest analyst rating for ARS Pharmaceuticals (NASDAQ:SPRY) was provided by Roth Capital, and ARS Pharmaceuticals initiated their buy rating.
When was the last upgrade for ARS Pharmaceuticals (SPRY)?
The last upgrade for ARS Pharmaceuticals Inc happened on August 13, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for ARS Pharmaceuticals Inc.
When was the last downgrade for ARS Pharmaceuticals (SPRY)?
The last downgrade for ARS Pharmaceuticals Inc happened on September 20, 2023 when William Blair changed their price target from N/A to N/A for ARS Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ARS Pharmaceuticals (SPRY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on September 4, 2025 so you should expect the next rating to be made available sometime around September 4, 2026.
Is the Analyst Rating ARS Pharmaceuticals (SPRY) correct?
While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a initiated with a price target of $0.00 to $40.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $8.17, which is within the analyst’s predicted range.
